Literature DB >> 25951098

Risk stratification by the lower limit of normal of FEV1/FVC for postoperative outcomes in patients with COPD undergoing thoracic surgery.

Satoko Osuka1, Naozumi Hashimoto2, Koji Sakamoto3, Kenji Wakai4, Kohei Yokoi5, Yoshinori Hasegawa6.   

Abstract

BACKGROUND: Mounting evidence suggests that airway obstruction defined by the lower limit of normal (LLN) of forced expiration volume in 1s (FEV1)/forced vital capacity (FVC) might be an important predictor of mortality in patients with an FEV1/FVC ratio below 0.70. Although better risk stratification for postoperative outcomes in patients with chronic obstructive pulmonary disease (COPD) undergoing thoracic surgery is warranted, whether an FEV1/FVC ratio below 0.70 but above the LLN (i.e., in-between) could identify patients at risk for adverse postoperative outcomes has not been fully evaluated.
METHODS: To determine the clinical impact of this "in-between" group of patients with COPD, we evaluated whether classification of the in-between group and the COPD group with FEV1/FVC ratios below 0.70 and below the LLN could provide more accurate risk stratification for postoperative outcomes in COPD patients undergoing thoracic surgery.
RESULTS: The criterion of LLN classified 302 patients with an FEV1/FVC ratio below 0.70 into either the in-between group (124 cases) or the COPD group (178 cases). The COPD group showed a 3-fold increase in prolonged oxygen therapy (POT) and a 50% increase in prolonged postoperative stay (PPS), as compared with the in-between group, with an adjusted odds ratio of 3.068 (95% confidence interval: 1.806-5.213) for POT.
CONCLUSIONS: Based on the finding that the in-between group could independently identify patients at risk for adverse postoperative outcomes, LLN assessment of the FEV1/FVC ratio might provide more accurate risk stratification in COPD patients undergoing thoracic surgery.
Copyright © 2015 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  0.70 fixed ratio; Chronic obstructive lung disease; Lower limit of normal; Risk stratification; Thoracic surgery

Mesh:

Year:  2015        PMID: 25951098     DOI: 10.1016/j.resinv.2015.01.005

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  5 in total

1.  Non-intubated thoracoscopic surgery for lung cancer in patients with impaired pulmonary function.

Authors:  Man-Ling Wang; Ming-Hui Hung; Hsao-Hsun Hsu; Kuang-Cheng Chan; Ya-Jung Cheng; Jin-Shing Chen
Journal:  Ann Transl Med       Date:  2019-02

2.  Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study.

Authors:  Naozumi Hashimoto; Akira Ando; Shingo Iwano; Koji Sakamoto; Shotaro Okachi; Asuka Matsuzaki; Yu Okada; Kenji Wakai; Kohei Yokoi; Yoshinori Hasegawa
Journal:  BMC Pulm Med       Date:  2018-01-05       Impact factor: 3.317

3.  Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy.

Authors:  Norihito Omote; Naozumi Hashimoto; Masahiro Morise; Koji Sakamoto; Shinichi Miyazaki; Akira Ando; Yoshio Nakahara; Yoshinori Hasegawa
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-11

4.  <Editors' Choice> Renewed Japanese spirometric reference variables and risk stratification for postoperative outcomes in COPD patients with resected lung cancer.

Authors:  Yu Okada; Naozumi Hashimoto; Shingo Iwano; Koji Kawaguchi; Takayuki Fukui; Koji Sakamoto; Kenji Wakai; Kohei Yokoi; Yoshinori Hasegawa
Journal:  Nagoya J Med Sci       Date:  2019-08       Impact factor: 1.131

5.  Liuweibuqi capsules improve pulmonary function in stable chronic obstructive pulmonary disease with lung-qi deficiency syndrome by regulating STAT4/STAT6 and MMP-9/TIMP-1.

Authors:  Dan-Dan Shen; Zhong-Hui Yang; Ji Huang; Fei Yang; Zi-Wei Lin; Ying-Fei Ou; Min-Hao Hu
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.